# INO catalysts: INOVIO PHARMACEUTICALS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ino/catalysts

> INOVIO PHARMACEUTICALS, INC. (INO) has 1 upcoming catalyst. The next is the INO-3107 PDUFA date, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for INO?

INOVIO PHARMACEUTICALS, INC. (INO) has 1 upcoming catalyst. The next is the INO-3107 PDUFA date, Q1 2027. Press release filed with the SEC (EX-99): "INOVIO estimates that current cash, cash equivalents and short-term investments balances will support operations into the first quarter of 2027, beyond the target PDUFA date for INO-3107." [Calendar and source filings](https://sec-api.dev/companies/ino/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001055726-26-000019, https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm (retrieved 2026-11-12). Last confirmed 2026-05-13. Cite: https://sec-api.dev/companies/ino/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | INOVIO PHARMACEUTICALS, INC. |
| Ticker | INO (Nasdaq) |
| SEC CIK | 1055726 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ino |

## Cash runway

Cash $48.4M as of 2026-09-30; quarterly burn $15.3M; about 9.5 months of runway at that rate (XBRL company facts, accession 0001055726-26-000029).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 14, 2024 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572624000053/ino-93024x8kex991.htm)) |
| March 18, 2025 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000013/ino-123124x8kex991.htm)) |
| May 13, 2025 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000027/ino-33125x8kex991.htm)) |
| 2H 2025 | [INO-3107 NDA/BLA submission](https://sec-api.dev/pdufa/ino-3107) | INO |  | scheduled | "INOVIO plans to begin rolling submission of the BLA in mid-2025 under FDA's accelerated approval program, subject to FDA concurrence, with the goal of completing the submission in the second half of 2025 and receiving FDA acceptance of the submission by the end of the year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000027/ino-33125x8kex991.htm)) |
| Jul 2025 | [INO-3107 NDA/BLA acceptance](https://sec-api.dev/pdufa/ino-3107) | INO |  | completed | "In addition, we have several series of warrants outstanding that may be exercised at any time; for example, as of the date hereof, we have outstanding Series A warrants to purchase up to 13,857,144 shares of common stock in July 2025, which will expire on the date that is the earlier of (i) 12 months from the date of issuance or (ii) 30 days after the date on which we first publicly disclose, whether by press release or Form 8-K filing, the FDA's acceptance of a BLA for INO-3107." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000063/ino-20250930.htm)) |
| August 12, 2025 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000056/ino-63025x8kex991.htm)) |
| Nov 2025 | [INO-3107 NDA/BLA acceptance](https://sec-api.dev/pdufa/ino-3107) | INO |  | scheduled | "We requested rolling submission of our BLA for INO-3107 in July 2025 and reported in November 2025 that we had completed the BLA submission, with the goal of receiving file acceptance by the FDA by the end of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000063/ino-20250930.htm)) |
| Nov 2025 | [INO-3107 NDA/BLA submission](https://sec-api.dev/pdufa/ino-3107) | INO |  | completed | "In November 2025, we announced that we had submitted our BLA for INO-3107 as a treatment for adults with RRP under the FDA's accelerated approval program." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm)) |
| November 10, 2025 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000064/ino-93025x8kex991.htm)) |
| December 29, 2025 | [INO-3107 NDA/BLA acceptance](https://sec-api.dev/pdufa/ino-3107) | INO | RRP and set the Prescription Drug User Fee Act | completed | "As described in Item 8.01 below, on December 29, 2025, Inovio Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted the Company's Biologic License Application ("BLA") for INO-3107, an investigational immunotherapy for the treatment of recurrent respiratory papillomatosis ("RRP") in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1055726/000119312525332322/d78035d8k.htm)) |
| February 6, 2026 | [INO-3107 NDA/BLA submission](https://sec-api.dev/pdufa/ino-3107) | INO |  | completed | "For example, a purported shareholder class action complaint was filed against us on February 6, 2026 and three purported shareholder derivative complaints have been filed against us on March 5, 2026, March 16, 2026 and July 23, 2026, naming us and our executive officers as defendants, and alleging that we made materially false and misleading statements regarding the submission to the FDA and the FDA's review timeline for our BLA for INO-3107 in violation of certain federal securities laws." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1055726/000119312526326370/d155272d424b5.htm)) |
| March 12, 2026 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000009/ino-123125x8kex991.htm)) |
| mid-2026 | [INO-3107 PDUFA date](https://sec-api.dev/pdufa/ino-3107) | INO |  | delayed | "FDA has previously awarded breakthrough therapy designation for INO-3107 and INOVIO plans to request priority review of its BLA, which if granted would allow for an FDA approval decision (PDUFA date) in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000027/ino-33125x8kex991.htm)) |
| May 2026 | [VGX-3100 topline data readout](https://sec-api.dev/pdufa/vgx-3100) | INO |  | completed, positive | "In May 2026, INOVIO's partner for VGX-3100 in Greater China, ApolloBio, announced positive topline results from its pivotal Phase 3 trial of VGX-3100 as a potential treatment for cervical dysplasia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-63026x8kex991.htm)) |
| May 13, 2026 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm)) |
| August 12, 2026 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-63026x8kex991.htm)) |
| October 30, 2026 | [INOVIO PHARMACEUTICALS, INC. FDA approval](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed, approved | "INOVIO Announces FDA Accelerated Approval of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000119312526442648/d150457dex991.htm)) |
| October 30, 2026 | [INO-3107 NDA/BLA acceptance](https://sec-api.dev/pdufa/ino-3107) | INO |  | completed | " the FDA's acceptance of our BLA for INO-3107 with a PDUFA target action date set for October 30, 2026, and the yet-to-be scheduled meeting with the FDA to discuss eligibility for the accelerated approval program;" ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1055726/000119312526451932/d141720d424b5.htm)) |
| October 30, 2026 | [INO-3107 PDUFA date](https://sec-api.dev/pdufa/ino-3107) | INO |  | scheduled | "The FDA's review of the BLA for INO-3107 continues to advance under the Agency's accelerated approval program toward a PDUFA target action date of October 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-63026x8kex991.htm)) |
| November 10, 2026 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000030/ino-93026x8kex991.htm)) |
| Q1 2027 | [INO-3107 PDUFA date](https://sec-api.dev/pdufa/ino-3107) | INO |  | scheduled | "INOVIO estimates that current cash, cash equivalents and short-term investments balances will support operations into the first quarter of 2027, beyond the target PDUFA date for INO-3107." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm)) |

## Drugs

- [INO-3107](https://sec-api.dev/pdufa/ino-3107): rrp and set the prescription drug user fee act, recurrent respiratory papillomatosis
- [VGX-3100](https://sec-api.dev/pdufa/vgx-3100): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ino/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "INO catalysts: INOVIO PHARMACEUTICALS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ino/catalysts

```bibtex
@misc{secapidev_companies_ino_catalysts_20261116,
  title        = {INO catalysts: INOVIO PHARMACEUTICALS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ino/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ino_catalysts_20261116","title":"INO catalysts: INOVIO PHARMACEUTICALS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ino/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
